The main functions and structural modifications of tripeptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) as a chemotactic factor

Pharmazie

Volumn 63, Issue 11, 2008, Pages 779-783

  Yang, K H ^a   Fang, H ^a   Ye, J S ^a   Gong, J Z ^a   Wang, J T ^b   Xu, Wen Fang ^a  

^a SHANDONG UNIVERSITY   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; BLEOMYCIN A6; EGENESTEIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; LAVENDUSTIN A; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINOCICEPTION; ANTIVIRAL ACTIVITY; CELL SURFACE; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG PURIFICATION; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RECEPTOR BINDING; REVIEW;

ALOPECIA; ANALGESICS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CHEMOTACTIC FACTORS; HUMANS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56749158999     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8595     Document Type: Review

References (47)

1. Cavicchioni G, Monesi LG, Ferretti ME, Fabbri E, Rizzuti O, Spisani S (1998) fMLP-OMe analogs substituted at the methionine residue: an insight into the receptor properties. Arch Pharm (Weinheim) 331: 368-370.
2. Cavicchioni G, Spisani S (2001) A hydrophilic residue at position 2 can improve specific biological responses in fMLP-OMe analogs. J Pept Res 58: 257-262.
3. Cavicchioni G, Fraulini A, Turchetti M, Varani K, Falzarano S, Pavan B, Spisani S (2005) Biological activity of for-Met-Leu-Phe-OMe analogs: relevant substitutions specifically trigger killing mechanisms in human neutrophils. Eur J Pharmacol 512: 1-8.
4. Dugas H, Laroche M, Ptak M, Labbé H (1993) Synthesis, biological activity, conformational analysis by NMR and molecular modeling of N-formyl-L-Met-L-Pro-L-Phe-OMe, a proline analogue of the chemotactic peptide N-formyl-L-Met-L-Leu-L-Phe-OH. Int J Pept Protein Res 41: 595-605.
5. Fabbri E, Spisani S, Barbin L, Biondi C, Buzzi M, Traniello S, Zecchini GP, Ferretti ME (2000) Studies on fMLP-receptor interaction and signal transduction pathway by means of fMLP-OMe selective analogues. Cell Signal 12: 391-398.
6. Freer RJ, Day AR, Radding JA, Schiffmann E, Aswanikumar S, Showell HJ, Becker EL (1980) Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry 19: 2404-2410.
7. Gao JL, Lee EJ, Murphy PM (1999) Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med 189: 657-662.
8. Giordano C, Lucente G, Nalli M, Pagani Zecchini G, Paglialunga Paradisi M, Varani K, Spisani S (2003) Synthesis and activity of HCO-Met-Leu-Phe-OMe analogues containing beta-alanine or taurine at the central position. Farmaco 58: 1121-1130.
9. Giorgio C, Anna F, Sofia F, Susanna S (2006) Structure-activity relationship of for-L-Met-L-Leu-L-Phe-OMe analogues in human neutrophils. Bioorganic Chemistry 34: 298-318.
10. Higgins JD, Bridger GJ, Derian CK, Beblavy MJ, Hernandez PE, Gaul FE, Abrams MJ, Pike MC, Solomon HF (1996) N-terminus urea-substituted chemotactic peptides: new potent agonists and antagonists toward the neutrophil fMLF receptor. J Med Chem 39: 1013-1015.
11. Isturiz MA, Beigier-Bompadre M, Barrionuevo P, Alves-Rosa F, Palermo MS, Vulcano M (2004) Hypothesis: an alternative pathway for the regulation of inflammation. Medicina (B Aires) 64: 235-239.
12. Kim MK, Min S, Park YJ, Kim JH, Ryu SH, Bae YS (2007) Expression and functional role of formyl peptide receptor in human bone marrow-derived mesenchymal stem cells. FEBS Lett. 581: 1917-1922.
13. Kraus JL, Attardo G (1992) Synthesis and biological activities of new N- formylated methionyl peptides containing an α-substituted glycine residue. Eur Med Chem 27: 19-26.
14. Lavigne MC, Murphy PM, Leto TL, Gao JL (2002) The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe- stimulated activation of NADPH oxidase in murine neutrophils. Cell Immunol 218: 7-12.
15. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB, Ye RD, Wang JM (1999) Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 163: 6777-6784.
16. Le Y, Shen W, Li B, Gong W, Dunlop NM, Wang JM (1999) A new insight into the role of "old" chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4. Forum (Genova) 9: 299-314.
17. Le YY, Oppenheim JJ, Wang JM (2001) Cytokine Growth Factor Rev 12: 91-105.
18. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D (2000) Roles of PLC-b2 and -b3 and PI3kγ in chemoattractant-mediated signal transduction. Science 287: 1046-1049.
19. Li ZD, Li Y, Zhen YS (2002) Chemotactic peptide fMLP enhances antitumor activity of boanmycin. Ai Zheng 21: 828-832.
20. Morikawa K, Nayar R, Fidler IJ (1988) In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl- phenylalanine (FMLP) incorporated in liposomes. Cancer Immunol Immunother 27: 1-6.
21. Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC (1983) Monocyte Chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmacol 5: 307-314.
22. Obrist R, Sandberg AL (1983) Enhancement of macrophage invasion of tumors by administration of chemotactic factor-antitumor antibody conjugates. Cell Immunol 81: 169-174.
23. Obrist R, Schmidli J, Müller R, Gallati H, Obrecht JP (1991) Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: a phase I clinical trial. Cancer Immunol Immunother 32: 406-408.
24. Ogle JD, Noel JG, Sramkoski RM, Ogle CK, Alexander JW (1992) Effects of combination of tumor necrosis factor alpha and chemotactic peptide, f-Met-Leu-Phe, on phagocytosis of opsonized microspheres by human neutrophils. Inflammation 16: 57-68.
25. Pagani ZG, Morera E, Nalli M, Paglialunga PM, Lucente G, Spisani S (2001) Synthesis and activity on human neutrophil functions of fMLF-OMe analogs containing alkyl spacers at the central position. Farmaco 56: 851-858.
26. Ptasznik A, Traynor-Kaplan A, Bokoch GM (1995) G protein-coupled chemoattractant receptors regulate lyn tyrosine kinase-Shc adapter protein signaling complexes. J Biol Chem 270: 19969-19973.
27. Quehenberger O, Prossnitz ER, Cavanagh SL, Cochrane CG, Ye RD (1993) Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem 268: 18167-18175.
28. Radel SJ, Genco RJ, De Nardin E (1994) Structural and functional characterization of the human formyl peptide receptor ligand-binding region. Infect Immun. 62: 1726-1732.
29. 2+ homeostasis in polymorphonuclear leukocytes from chronic myeloid leukaemia patients. Mol Cancer 5: 65.
30. Shen W, Li B, Wetzel MA, Rogers TJ, Henderson EE, Su SB (2000) Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood 96: 2887-2894.
31. Shipp MA, Look AT (1993) Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 82: 1052-1070.
32. Shrivastava A (2007) Activation of macrophages with N-formyl- methionyl-leucyl-phenylalanine: involvement of protein kinase C and tyrosine kinase. Indian J Exp Biol 45: 755-763.
33. Sodhi A, Biswas SK (2002) fMLP-induced in vitro nitric oxide production and its regulation in murine peritoneal macrophages. J Leukoc Biol 71: 262-270.
34. Soehnlein O, Kenne E, Rotzius P, Eriksson EE, Lindbom L (2008) Neutrophil secretion products regulate anti-bacterial activity in monocytes and macrophages. Clin Exp Immunol 151: 139-145.
35. Spisani S, Traniello S, Cavicchioni G, Formaggio F, Crisma M, Toniolo C (2002) Probing structural requirements of fMLP receptor: on the size of the hydrophobic pocket corresponding to residue 2 of the tripeptide. J Pept Sci 8: 56-65.
36. Spisani S, Turchetti M, Varani K, Falzarano S, Cavicchioni G (2003) Hydrophilic residues at position 3 highlight unforeseen features of the fMLP receptor pocket. Eur J Pharmacol 469: 13-19.
37. Spisani S, Fraulini A, Varani K, Falzarano S, Cavicchioni G (2007) New chemotactic dimeric peptides show high affinity and potency at the human formylpeptide receptor. Eur J Pharmacol 567: 171-176.
38. Stefano P, Amalia DG, Milena DF, Mauro P, Giuseppe C (2004) Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides. Pain 109: 52-63.
39. Stephenson KA, Banerjee SR, Sogbein OO, Levadala MK, McFarlane N, Boreham DR, Maresca KP, Babich JW, Zubieta J, Valliant JF (2005) A new strategy for the preparation of peptide-targeted technetium and rhenium radiopharmaceuticals. The automated solid-phase synthesis, characterization, labeling, and screening of a peptide-ligand library targeted at the formyl peptide receptor. Bioconjug Chem 16: 1189-1195.
40. Torres M, Hall FL, O'Neill K (1993) Stimulation of human neutrophils with fMLP induces tyrosine phosphorylation and activation of two distinct mitogen-activated protein kinase. J Immunol 150: 1563-1578.
41. Torrini I, Pagani Zecchini G, Paglialunga Paradisi M, Lucente G, Gavuzzo E, Mazza F, Pochetti G, Traniello S, Spisani S (1994) Modified chemotactic peptides: synthesis, crystal conformation, and activity of For-Hse(Me)-Leu-Phe- OMe. Biopolymers 34: 1-9.
42. Tsuruki T, Takahata K, Yoshikawa M (2007) Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia. Biosci Biotechnol Biochem 71: 1198-1202.
43. Vulcano M, Alves MF, Minnucci FS, Cherñavsky AC, Isturiz MA (1998) N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits tumor necrosis factor-alpha (TNF-alpha) production on lipopolysaccharide (LPS)-stimulated human neutrophils. Clin Exp Immunol 113: 39-47.
44. Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ (2007) Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res 24: 2110-2119.
45. Wenzel SK, Arthur JM, Liu HY, Seifert R (1999) Quantitative analysis of formyl peptide receptor coupling to Giα1,Giα 2, and Giα3. J Biol Chem 274: 33259-33266.
46. Zecchini GP, Paradisi MP, Torrini I, Lucente G, Traniello S, Spisani S (1993) Cyclic analogs of chemotactic formylpeptides, I: Synthesis and biological activity of For-Cys-Leu-Phe-Cys-OMe. Arch Pharm (Weinheim) 326: 955-958.
47. Zlotnik A, Morales J, Hedrick JA (1999) Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 19: 1-47.